NEW YORK--(BUSINESS WIRE)--Sept. 18, 2006--ImClone Systems Incorporated (NASDAQ: IMCL) today announced that the U.S. District Court in Manhattan has issued a decision in favor of Yeda Research and Development Company in a case involving the inventorship of a patent that ImClone Systems licenses from sanofi-aventis. The Court ruled that three scientists associated with Yeda are sole inventors of the patent, which covers the use of certain monoclonal antibodies in combination with anti-neoplastic agents for the treatment of cancer.
